CytoMed Therapeutics (NASDAQ:GDTC) Announces Earnings Results

CytoMed Therapeutics (NASDAQ:GDTC) announced its earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.06 million for the quarter.

CytoMed Therapeutics Stock Down 2.9%

Shares of CytoMed Therapeutics stock opened at $1.00 on Wednesday. The stock’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.54. CytoMed Therapeutics has a 52 week low of $0.73 and a 52 week high of $3.68.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CytoMed Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, CytoMed Therapeutics has a consensus rating of “Sell”.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.